Immunotherapy-based Pet Cancer Therapeutics Market Research Report - Segmentation By Route of Administration (Oral, Injection); By Animal (Dogs, Cats); By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15923
Format:
Region: Global
Chapter 1. Global Immunotherapy-based Pet Cancer Therapeutics Market– Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Immunotherapy-based Pet Cancer Therapeutics Market – Executive Summary
2.1. Market Size & Forecast – (2024 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. Global Immunotherapy-based Pet Cancer Therapeutics Market– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. Global Immunotherapy-based Pet Cancer Therapeutics Market - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Immunotherapy-based Pet Cancer Therapeutics Market- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Immunotherapy-based Pet Cancer Therapeutics Market– By Route of Administration
6.1. Introduction/Key Findings
6.2. Oral
6.3. Injection
6.4. Y-O-Y Growth trend Analysis By Route of Administration
6.5. Absolute $ Opportunity Analysis By Route of Administration , 2024-2030
Chapter 7. Global Immunotherapy-based Pet Cancer Therapeutics Market– By Animal
7.1. Introduction/Key Findings
7.2. Dogs
7.3. Cats
7.4. Y-O-Y Growth trend Analysis By Animal
7.5. Absolute $ Opportunity Analysis By Animal , 2024-2030
Chapter 8. Global Immunotherapy-based Pet Cancer Therapeutics Market– By Application
8.1. Introduction/Key Findings
8.2. Lymphoma
8.3. Mast Cell Cancer
8.4. Melanoma
8.5. Mammary
8.6. Squamous Cell Cancer
8.7. Others
8.8. Y-O-Y Growth trend Analysis Application
8.9. Absolute $ Opportunity Analysis Application , 2024-2030
Chapter 9. Global Immunotherapy-based Pet Cancer Therapeutics Market, By Geography – Market Size, Forecast, Trends & Insights
9.1. North America
9.1.1. By Country
9.1.1.1. U.S.A.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. By Route of Administration
9.1.3. By Animal
9.1.4. By Application
9.1.5. Countries & Segments - Market Attractiveness Analysis
9.2. Europe
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Germany
9.2.1.3. France
9.2.1.4. Italy
9.2.1.5. Spain
9.2.1.6. Rest of Europe
9.2.2. By Route of Administration
9.2.3. By Animal
9.2.4. By Application
9.2.5. Countries & Segments - Market Attractiveness Analysis
9.3. Asia Pacific
9.3.2. By Country
9.3.2.2. China
9.3.2.2. Japan
9.3.2.3. South Korea
9.3.2.4. India
9.3.2.5. Australia & New Zealand
9.3.2.6. Rest of Asia-Pacific
9.3.2. By Route of Administration
9.3.3. By Animal
9.3.4. By Application
9.3.5. Countries & Segments - Market Attractiveness Analysis
9.4. South America
9.4.3. By Country
9.4.3.3. Brazil
9.4.3.2. Argentina
9.4.3.3. Colombia
9.4.3.4. Chile
9.4.3.5. Rest of South America
9.4.2. By Route of Administration
9.4.3. By Animal
9.4.4. By Application
9.4.5. Countries & Segments - Market Attractiveness Analysis
9.5. Middle East & Africa
9.5.4. By Country
9.5.4.4. United Arab Emirates (UAE)
9.5.4.2. Saudi Arabia
9.5.4.3. Qatar
9.5.4.4. Israel
9.5.4.5. South Africa
9.5.4.6. Nigeria
9.5.4.7. Kenya
9.5.4.8. Egypt
9.5.4.9. Rest of MEA
9.5.2. By Route of Administration
9.5.3. By Animal
9.5.4. By Application
9.5.5. Countries & Segments - Market Attractiveness Analysis
Chapter 10. Global Immunotherapy-based Pet Cancer Therapeutics Market– Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1 AB Science
10.2. Boehringer Ingelheim International GmbH
10.3. Elanco Animal Health Incorporated
10.4. ELIAS Animal Health LLC
10.5. Karyopharm Therapeutics
10.6. Pfizer Inc.
10.7. Regeneus Ltd.
10.8. Rhizen Pharmaceuticals AG
10.9. Torigen Pharmaceuticals Inc.
10.10. VetDC Inc.
10.11. Virbac
10.12. Zoetis Inc.
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Global Immunotherapy-based Pet Cancer Therapeutics Market was estimated to be worth USD 5.5 billion in 2022 and is projected to reach a value of USD 12.95 billion by 2030, growing at a CAGR of 11.3% during the forecast period 2023-2030
Growing the human-animal relationship and pet ownership can help the industry grow and Modern technical developments that will push the market growth are the factors driving the Global Immunotherapy-based Pet Cancer Therapeutics Market.
The market's expansion may be hampered by high treatment costs.
Melanoma application type is the fastest growing in the Global Immunotherapy-based Pet Cancer Therapeutics Market.
Asia-Pacific region is the fastest growing in the Global Immunotherapy-based Pet Cancer Therapeutics Market.
